FDA Compounding Enforcement Could Have Been More Aggressive, Hamburg Acknowledges; Tense Hearing Continues Legislative Stalemate
This article was originally published in The Pink Sheet Daily
House Republicans remain unconvinced that FDA needs additional enforcement powers as Commissioner Hamburg is grilled on why the agency didn’t employ its current forceful inspection approach in the run-up to New England Compounding Center tragedy.
You may also be interested in...
Agency releases 483 forms from a post-crises inspection push; the effort may help FDA illustrate its inspection capabilities to Congress and states and indicate the agency’s oversight plans under the new authority it has proposed.
Congress should give FDA more flexibility to administer orphan designations, such as the ability to revoke designations later if the disease prevalence grows beyond the rare disease threshold.
ACIP defers vote on who should be inoculated first until it has data on a specific product, but vaccine acceptance among different groups could be weighed as factor in setting distribution priorities, committee members suggest.